In tamoxifen-resistant ER+ breast cancer, the high level of FOXA1 could be reduced by sorafenib and nilotinib, leading to the re-sensitization of the tamoxifen-resistant cells [28]. The gene discussed is FOXA1; the disease is breast carcinoma.